Page 2420 - Williams Hematology ( PDFDrive )

2390 Part XIII: Transfusion Medicine Chapter 139: Preservation and Clinical Use of Platelets 2391

64. Heddle NM, Arnold DM, Boye D, et al: Comparing the efficacy and safety of apher- 80. Lin L, Cook DN, Wiesehahn GP, et al: Photochemical inactivation of viruses and bac-
esis and whole blood derived platelet transfusions: A systematic review. Transfusion teria in platelet concentrates by use of a novel psoralen and long-wavelength ultraviolet
48:1447, 2008. light. Transfusion 37:423, 1997.
65. Triulzi DJ, Assmann SF, Strauss RG, et al: The impact of platelet transfusion charac- 81. Ruane PH, Edrich R, Gampp D, et al: Photochemical inactivation of selected viruses
teristics on posttransfusion platelet increments and clinical bleeding in patients with and bacteria in platelet concentrates using riboflavin and light. Transfusion 44:877,
hypo-proliferative thrombocytopenia. Blood 119:5553, 2012. 2004.
66. Heddle NM, Arnold DM, Boye D, et al: Comparing the efficacy and safety of apher- 82. Fast LD, DiLeone G, Li J, Goodrich R: Functional inactivation of white blood cells by
esis and whole blood-derived platelet transfusions: A systematic review. Transfusion Mirasol treatment. Transfusion 46:642, 2006.
48:1447, 2008. 83. Grass JA, Wafa T, Reames A, et al: Prevention of transfusion-associated graft-versus-
67. Shehata NS, Tinmouth A, Naglie G, et al: ABO-identical versus nonidentical platelet host disease by photochemical treatment. Blood 93:3140, 1999.
transfusion: A systematic review. Transfusion 49:2442, 2009. 84. AuBuchon JP, Herschel L, Roger J, et al: Efficacy of apheresis platelets treated with ribo-
68. Pavenski K, Warkentin TE, Shen H, et al: Posttransfusion platelet count increments flavin and ultraviolet light for pathogen reduction. Transfusion 45:1335, 2005.
after ABO-compatible versus ABO-incompatible platelet transfusions in noncancer 85. Snyder E, Raife T, Lin L, et al: Recovery and life span of 111indium-radiolabeled plate-
patients: An observational study. Transfusion 50:1552, 2010. lets treated with pathogen inactivation with amotosalen HCl (S-59) and ultraviolet A
69. Kaufman RM, Assmann SF, Triulzi DJ, et al: Transfusion-related adverse events in the light. Transfusion 44:1732, 2004.
Platelet Dose study. Transfusion 55:144, 2015. 86. Goodrich RP, Li J, Pieters H, et al: Correlation of in vitro platelet quality measurements
70. Bowden RA, Slichter SJ, Sayers M, et al: A comparison of filtered leukocyte-reduced with in vivo platelet viability in human subjects. Vox Sang 90:279, 2006.
and cytomegalovirus (CMV) seronegative blood products for the prevention of 87. McCullough J, Vesole DH, Benjamin RJ, et al: Therapeutic efficacy and safety of plate-
transfusion-associated CMV infection after marrow transplantation. Blood 86:3598, 1995. lets treated with a photochemical process for pathogen inactivation: The SPRINT trial.
71. Heddle NM, Blajchman MA, Meyer RM, et al: A randomized controlled trial compar- Blood 104:1534, 2004.
ing the frequency of acute reactions to plasma-removed platelets and prestorage WBC- 88. Ostrowski SR, Bochsen L, Windelov NA, et al: Hemostatic function of buffy coat
reduced platelets. Transfusion 42:556, 2002. platelets in additive solution treated with pathogen reduction technology. Transfusion
72. Dzik S, AuBuchon J, Jeffries L, et al: Leukocyte reduction of blood components: Public 51:344, 2011.
policy and new technology. Transfus Med Rev 14:34, 2000. 89. Wagner SJ, Moroff G, Katz AJ, Friedman LI: Comparison of bacterial growth in single
73. Vamvakas EC, Blajchman MA: Deleterious clinical effects of transfusion-associated and pooled platelet concentrates after deliberate inoculation and storage. Transfusion
immunomodulation: Fact or fiction? Blood 97:1180, 2001. 35:298, 1995.
74. Leitman SF: Use of blood cell irradiation in the prevention of posttransfusion graft- 90. Vostal JG: Efficacy evaluation of current and future platelet transfusion products. J
versus-host disease. Transfus Sci 10:219, 1989. Trauma 60(Suppl):S78, 2006.
75. Moroff G, George VM, Siegel AM, Luban NL: The influence of irradiation on stored 91. Slichter SJ: Platelet transfusion: Future directions. Vox Sang 87(Suppl 2):S47, 2004.
platelets. Transfusion 26:453, 1986. 92. Slichter SJ, Bolgiano D, Corson J, et al: Extended storage of platelet-rich plasma pre-
76. Slichter SJ, Davis K, Enright H, et al: Factors affecting post-transfusion platelet incre- pared platelet concentrates in plasma or plasmalyte. Transfusion 50:2199, 2010.
ments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic 93. Slichter SJ, Bolgiano D, Corson J, et al: Extended storage of buffy coat platelet concen-
patients. Blood 105:4106, 2005. trates in plasma or plasmalyte. Transfusion 54:2283, 2014.
77. Slichter SJ, Bolgiano D, Kao KJ, et al: Persistence of lymphocytotoxic antibodies in 94. Slichter SJ, Bolgiano D, Jones MK, et al: Viability and function of 8-day stored apheresis
patients in the Trial to Reduce Alloimmunization to Platelets: Implications for using platelets. Transfusion 46:1763, 2006.
modified blood products. Transfus Med Rev 25:102, 2011. 95. Slichter SJ, Bolgiano D, Corson J, et al: Extended storage of autologous apheresis plate-
78. Saxonhouse M, Slayton W, Sola MC: Platelet transfusions in the infant and child, in lets in plasma. Vox Sang 104:324, 2013.
Handbook of Pediatric Transfusion Medicine, edited by CD Hillyer, NL Luban, RG 96. Slichter SJ, Corson J, Jones MK, et al: Exploratory studies of extended storage of apher-
Strauss, p 253. Elsevier Academic Press, San Diego, CA, 2004. esis platelets in a platelet additive solution (PAS). Blood 123:271, 2014.
79. Schoenfeld H, Muhm M, Doepfmer UR, et al: The functional integrity of platelets in
volume-reduced platelet concentrates. Anesth Analg 100:78, 2005.

Kaushansky_chapter 139_p2381-2392.indd 2391 9/18/15 2:23 PM